Daniel Jericó

Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

Lei Jiang, Pedro Berraondo, Daniel Jericó et al. · Nature Medicine · 2018 · 180 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +8

High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach

Isabel Solares, Laura Izquierdo‐Sánchez, Montserrat Morales‐Conejo et al. · Biomedicines · 2021 · 22 citations · Full text

Medicine, Biochemistry, Endocrinology +17

mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

Daniel Jericó, Karol M. Córdoba, Lei Jiang et al. · Molecular Therapy — Nucleic Acids · 2021 · 20 citations · Full text

Life Sciences, Biochemistry, Pharmacology +15

Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

Karol M. Córdoba, Irantzu Serrano-Mendioroz, Daniel Jericó et al. · Science Translational Medicine · 2022 · 16 citations · Full text

Medicine, Neuroscience, Pharmacology +14

Disease pharmacokinetic–pharmacodynamic modelling in acute intermittent porphyria to support the development of <scp>mRNA</scp>‐based therapies

Zinnia P. Parra‐Guillén, Antonio Fontanellas, Lei Jiang et al. · British Journal of Pharmacology · 2020 · 15 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17